I Jalenques1,2, F Rondepierre1, C Massoubre3,4, E Haffen5, J P Grand6,7, B Labeille8, J L Perrot8, F Aubin9,10, F Skowron11, A Mulliez12, M D'Incan13. 1. CHU Clermont-Ferrand, Service de Psychiatrie de l'Adulte A et Psychologie Médicale, Pôle de Psychiatrie, F-63003, Clermont-Ferrand, France. 2. Clermont Université, UFR Médecine, Université d'Auvergne Clermont 1, Equipe d'Accueil 7280, F-63001, Clermont-Ferrand, France. 3. CHU St-Etienne, Service de Psychiatrie, 42055, Saint-Etienne, France. 4. University Jean Monnet, 42100, Saint-Etienne, France. 5. Department of Clinical Psychiatry, CIC 1431 INSERM and EA 481 Neurosciences, University Hospital of Besançon, 25030, Besançon, France. 6. CHS Le Valmont, Monteleger, France. 7. Urgences et Psychiatrie de Liaison, Hôpital Général de Valence, Valence, France. 8. Service de Dermatologie, CHU Hôpital Nord, Saint-Etienne, France. 9. Université de Franche Comté, EA3181, Besançon, France. 10. Centre Hospitalier Universitaire, Service de Dermatologie, Besançon, France. 11. Service de Dermatologie, CH de Valence, 26000, Valence, France. 12. Direction de la Recherche Clinique et de l'Innovation, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France. 13. Université d'Auvergne, Service de Dermatologie, CHU Clermont-Ferrand, 63000, Clermont-Ferrand, France.
Abstract
BACKGROUND: Psychiatric disorders have been extensively documented in patients with systemic lupus erythematosus (SLE). However, the prevalence of psychiatric disorders in patients with skin-restricted lupus (SRL) remains unknown, although SRL is more common than SLE. OBJECTIVES: To assess current and lifetime prevalence of Axis I psychiatric disorders among outpatients with SRL and to examine the factors associated with psychiatric disorders among such patients. METHODS: A multicentre case-control study involving outpatients with SRL and controls matched for sex, age and education level. The Mini International Neuropsychiatric Interview was used for psychiatric evaluation. RESULTS: We evaluated 75 patients and 150 controls. Of these, 49% of patients vs. 13% of controls fulfilled the criteria for at least one current psychiatric disorder (P < 0·001). The following disorders were significantly more frequent among patients than controls: current and lifetime major depressive disorder (9% vs. 0%, P < 0·001 and 44% vs. 26%, P = 0·01), generalized anxiety disorder (23% vs. 3%, P < 0·001 and 35% vs. 19%, P = 0·03), panic disorder (7% vs. 0%, P = 0·004 and 21% vs. 3%, P < 0·001), current suicide risk (24% vs. 7%, P = 0·003), alcohol dependence (7% vs. 0%, P = 0·004) and lifetime agoraphobia (20% vs. 9%, P = 0·01). Lupus duration and lupus past treatment by thalidomide were significantly higher among patients with current psychiatric disorders. CONCLUSIONS: This study demonstrates a high prevalence of several psychiatric disorders (anxiety, depression, suicide risk, alcohol dependence) in patients with SRL.
BACKGROUND:Psychiatric disorders have been extensively documented in patients with systemic lupus erythematosus (SLE). However, the prevalence of psychiatric disorders in patients with skin-restricted lupus (SRL) remains unknown, although SRL is more common than SLE. OBJECTIVES: To assess current and lifetime prevalence of Axis I psychiatric disorders among outpatients with SRL and to examine the factors associated with psychiatric disorders among such patients. METHODS: A multicentre case-control study involving outpatients with SRL and controls matched for sex, age and education level. The Mini International Neuropsychiatric Interview was used for psychiatric evaluation. RESULTS: We evaluated 75 patients and 150 controls. Of these, 49% of patients vs. 13% of controls fulfilled the criteria for at least one current psychiatric disorder (P < 0·001). The following disorders were significantly more frequent among patients than controls: current and lifetime major depressive disorder (9% vs. 0%, P < 0·001 and 44% vs. 26%, P = 0·01), generalized anxiety disorder (23% vs. 3%, P < 0·001 and 35% vs. 19%, P = 0·03), panic disorder (7% vs. 0%, P = 0·004 and 21% vs. 3%, P < 0·001), current suicide risk (24% vs. 7%, P = 0·003), alcohol dependence (7% vs. 0%, P = 0·004) and lifetime agoraphobia (20% vs. 9%, P = 0·01). Lupus duration and lupus past treatment by thalidomide were significantly higher among patients with current psychiatric disorders. CONCLUSIONS: This study demonstrates a high prevalence of several psychiatric disorders (anxiety, depression, suicide risk, alcohol dependence) in patients with SRL.
Authors: Jennifer Hong; Laura Aspey; Gaobin Bao; Tamara Haynes; S Sam Lim; Cristina Drenkard Journal: Am J Clin Dermatol Date: 2019-06 Impact factor: 7.403